Vaskar Saha

Catriona Parker2
Ashish Masurekar2
Learn More
We focus on the problem of prediction with confidence and describe a recently developed learning algorithm called transductive confidence machine for making qualified region predictions. Its main advantage, in comparison with other classifiers, is that it is well-calibrated, with number of prediction errors strictly controlled by a given predefined(More)
Currently over 95% of children who are diagnosed with Acute Lym-phoblastic Leukaemia in the UK are enrolled into Medical Research Council trials. The trial protocol specifies that following initial treatment there is a 2-3 year maintenance period during which drug dosage decisions are made weekly according to a set of pre-defined rules. These rules are(More)
  • Catriona Parker, Rachel Waters, Carly Leighton, Jeremy Hancock, Rosemary Sutton, Anthony V Moorman +9 others
  • 2010
BACKGROUND Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens. METHODS This open-label randomised trial was undertaken in(More)
OBJECTIVES To assess the acceptability to clinicians of a web-based decision support system designed to assist with dosage adjustments during maintenance therapy for childhood Acute Lymphoblastic Leukaemia (ALL), and to evaluate the potential impact of the system on decision-making and dosage calculations. DESIGN Balanced-block crossover experiment with(More)
Despite the high cure rates in childhood acute lymphoblastic leukemia (ALL), relapsed ALL remains a significant clinical problem. Genetic heterogeneity does not adequately explain variations in response to therapy. The chemoprotective tumor microenvironment may additionally contribute to disease recurrence. This study identifies metabolic reprogramming of(More)
  • Jane Holmes, Sharon Love, Vaskar Saha, Arend von Stackelberg
  • 2015
Survival of children with acute lymphoblastic leukemia (ALL) has improved considerably over the past few decades , but relapsed ALL remains difficult to treat, particularly in those whose relapse puts them in a high risk (HR) group. Little progress has been made during the last two decades in the HR group despite several new drugs being investigated. The(More)
  • Ashish Narayan Masurekar, Catriona A. Parker, Milensu Shanyinde, Anthony V. Moorman, Jeremy P. Hancock, Rosemary Sutton +11 others
  • 2014
UNLABELLED The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A(More)
  • 1